We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Drug Co. Claims Licensee Breached ProQuin Deal

Law360 (December 18, 2006, 12:00 AM EST) -- A specialty pharmaceutical company said Monday that a New Jersey drug company has failed to make good on a $10 million license fee payment and has not used commercially reasonable efforts to market its drug for urinary tract infections.

Depomed Inc., based in Menlo Park, Calif., said it has notified Esprit Pharma Inc. of breaking the companies’ exclusive license and marketing agreement for ProQuin XR, a once-daily extended release form of ciprofloxacin.

Esprit, based in East Brunswick, N.J., did not pay the $10 million for a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.